Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field.
Topics being addressed by individual working groups include:
View current and past Task Force members via the links below:
In the video below, published by OncLive, watch as current SITC President Dr. Lisa Butterfield discusses the Immune Biomarkers Task Force.
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic Evaluation of Immune Regulation and Modulation Journal for ImmunoTherapy of Cancer, March 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011
Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Taskforce Journal of Translational Medicine, December 2010
A Systematic Approach to Biomarker Discovery; Preamble to "the iSBTc-FDA Taskforce on Immunotherapy Biomarkers" Journal of Translational Medicine, December 2008
NCI/CCR and SITC co-sponsored a 2016 Biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.
The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A report of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017. Click here to read Immunotherapy Biomarkers 2016: Overcoming the Barriers. Also, to learn more about the event and its schedule, click here.
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Final Program Released
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER Professor Shimon ...
This message was posted by a user wishing to remain anonymous Another Great Pittsburgher Dies - Philanthropist Henry Hillman led the renaissance of Pittsburgh's rebirth, a benefactor of the Hillman Cancer Center, an NCI Designated Cancer Center. http://www.post-gazette.com/local/city/2017/04/14/Philanthropist-Henry-Hillman-dies/stories/201704140181
Published April 11, 2017, in JAMA are the United States Preventative Services Task Force new recommendations for the surveillance of Prostate Cancer. The USPSTF recommends that the decision to have a DRE and prostate screening with PSA should be up ...
Immunotherapy@Brisbane 2017 Register online before Friday April 21! Leading International Speakers
EMBO KEYNOTE LECTURE Professor Sir Marc Feldmann Kennedy Institute of Rheumatology, University of Oxford, UK KEY SPEAKER ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org